Document is current
Any future updates will be listed below
-
Authors
Cai, Jun https://orcid.org/0000-0001-9495-1226
Deng, Xiaowei
Yang, Juan https://orcid.org/0000-0001-5028-2227
Sun, Kaiyuan
Liu, Hengcong https://orcid.org/0000-0003-2591-2201
Chen, Zhiyuan
Peng, Cheng
Chen, Xinhua
Wu, Qianhui
Zou, Junyi
Sun, Ruijia
Zheng, Wen
Zhao, Zeyao
Lu, Wanying
Liang, Yuxia
Zhou, Xiaoyu
Ajelli, Marco
Yu, Hongjie https://orcid.org/0000-0002-6335-5648
-
Funding
Funding for this research was provided by:
National Science Foundation of China | Key Programme (82130093)
- License Information
-
More Information
Article History
Received: 22 March 2022
Accepted: 3 May 2022
First Online: 10 May 2022
Competing interests
: H.Y. received research funding from Sanofi Pasteur, GlaxoSmithKline, Yichang HEC Changjiang Pharmaceutical Company, Shanghai Roche Pharmaceutical Company and SINOVAC Biotech Ltd. Except for research funding from SINOVAC Biotech Ltd, which is related to the data analysis of clinical trials of immunogenicity and safety of CoronaVac, the others are not related to COVID-19. M.A. has received research funding from Seqirus; the funding is not related to COVID-19. All the other authors have no competing interests.
